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Aim: To determine whether changes in orthoptic status take place during withdrawal from heroin and/or
methadone.
Method: A prospective study of patients, using a repeated measures design, attending a 5 day naltrexone
compressed opiate detoxification programme.
Results: 83 patients were seen before detoxification (mean age 27.1 (SD 4.6) years) and 69 after
detoxification. The horizontal angle of deviation became less exo/more eso at distance (p,0.001) but no
significant change was found at near (p = 0.069). Stereoacuity, visual acuity, and convergence were found
to be reduced in the immediate post-detoxification period. Prism fusion range, refractive error, subjective
accommodation, and objective accommodation at 33 cm did not reduce but a small decrease was found
in objective accommodation at 20 cm.
Conclusions: The eso trend found in these patients may be responsible for the development of acute
concomitant esotropia in some patients undergoing heroin detoxification. However, the mechanism for this
trend does not appear to be caused by divergence insufficiency or sixth nerve palsy.
H
immelsbach1 stated: ‘‘Occasionally a patient will
complain of double vision’’ on abrupt withdrawal from
heroin. The incidence of ‘‘diplopia and/or blurred
vision’’ during withdrawal has been reported as between
10% and 33.3%.2 Conversely, in a series of 100 patients
admitted to a drug treatment centre, none complained of a
change in vision.3 Small case series of patients presenting
with esotropia following heroin detoxification have appeared
in the literature4–6 and diplopia has been associated with the
use of chlorpromazine (Largactil) in one patient.7 Exotropia
has been reported in two cases on intake of heroin.6
This study was undertaken to determine the incidence of
problems immediately after heroin and/or methadone detox-
ification and to record orthoptic and refractive measurements
before and immediately after detoxification. Further, patients
are compared with a control group.
METHODS
Patients were recruited over 9 consecutive weeks, from an in-
patient heroin detoxification centre at which a 5 day
naltrexone compressed opiate detoxification protocol is used
(table 1).8 Each patient was seen twice—once before
detoxification (day 1) and once before discharge (day 5).
Information sheets and consent forms were sent to patients
before admission. Consent was obtained on the day of
admission. Exclusion criteria were: presbyopes or pre-
presbyopes (41 years of age and above); severe learning
difficulties; neurological disorders; visual acuity of less than
6/60 in both eyes; visual acuity of less than 3/60 in either eye.
Staff from the centre volunteered as control participants and
followed the same exclusion criteria and procedure as below.
The study was approved by the local research ethics
committee.
On the day of admission (day 1), before sedation,
consenting patients underwent examination by one
researcher (AYF). All tests were performed with refractive
correction, if worn regularly. The order of testing was as in
the order of the description below. Details of other drug use
before admission and mode of opioid use were taken from
hospital notes.
For patients admitted in weeks 3–9, the time since the last
use and the time until the next heroin or methadone dose
would usually be taken were noted.
A cover test was performed at 33 cm and 6 metres. If a
subject was found to have a decompensating deviation at
near, the binocular visual acuity (BVA) was recorded.
Horizontal prism fusion range to a light target with
Bagolini glasses, was measured noting the break point (point
at which fusion failed). For analysis, the angle of deviation
(minus value for exo deviations and plus for eso deviations)
was added to the value of the prism at break point (absolute
value). In manifest strabismus the prism fusion range was
not undertaken. Stereoacuity was assessed using the TNO
stereotest. Prism cover test measurements were recorded; and
on right gaze and left gaze at 6 metres for subjects tested in
weeks 4–9. Monocular near visual acuity was measured using
a reduced Snellen chart and distance visual acuity at 100%
and 10% contrast using a Bailey-Lovie chart. Ocular move-
ments were assessed fixing a light and using a cover test.
Pupil size was assessed with a millimetre rule fixing the
examiner’s eye at approximately 50 cm. Using the RAF rule,
convergence was recorded and subjective accommodation for
both eyes open; each eye monocularly; and both eyes open
repeated. Objectively, refractive state was measured in either
eye (with both eyes open) using the Nikkon open field
autorefractor SRW 5000 while the subject was fixing at
6 metres (with and without fogging lens); 33 cm, and 20 cm
to a 6/6 target or smallest letter able to be seen.
On the morning of day 5 the same protocol was used for
performing the clinical tests, but some subjects were
unwilling or unable to complete testing because of tiredness
or sickness. Patients were asked if they had noticed any
problems with vision. The same examiner (AYF) repeated the
tests but did not refer to previous data sheets until testing
was completed. All tests were carried out in the same area on
both days under normal room lighting conditions, with the
Abbreviations: BVA, binocular visual acuity; MSE, mean spherical
equivalent; MW, Mann-Whitney; WSRT, Wilcoxon signed ranks test
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exception of three cases on day 5 who were unwell; limited
testing took place in these patients’ rooms.
Analysis
Near visual acuity9 and prism measurements are ordinal data
and non-parametric tests used (Wilcoxon signed ranks test
(WSRT); Mann-Whitney (MW); Friedman test). Parametric
analysis involved the use of t test (paired or unpaired) and
analysis of variance. Spearman’s test was used to determine
correlations and multivariate regression. Refractive data were
converted to mean spherical equivalent (MSE) for analysis.
RESULTS
Eighty three subjects were seen before detoxification, mean
age 27.1 (SD 4.6) years (range 18–40.5). Fifty five were
currently heroin users; 18 used methadone but topped up
with heroin; and 10 were currently using methadone only.
The mode of heroin use was or had been smoking 35;
intravenously 25; both 20. The remaining three subjects used
methadone and had rarely used heroin. Sixty nine subjects
were examined on day 5. Ten subjects formed the control
group, mean age 29.5 (7.4) years (range 20–39).
Seven patients were myopic and two hypermetropic. One
patient had had a blow to his left eye which resulted in
intermittent diplopia. One patient reported diplopia following
a previous detoxification attempt and one patient reported
diplopia if he started to withdraw from heroin.
The mean time from the last dose of heroin was 8.44 (7.76)
hours (n=53) and all except nine would normally have used
it again by the time of examination. The use of non-
prescribed drugs was frequent and listed in table 2 along with
prescribed heroin substitutes.
Fifty of 69 subjects seen on day 5 reported ocular
symptoms. While the majority (n=22) noted these on day
4, others noted them occurring across the other days (mainly
days 1–3). On day 5, 26 felt that symptoms were improving,
one worsening, and there was no change in the others.
Symptoms were blur all distances n=12; blur near only
n=1; blur distance only n=4; diplopia n=14; blur and
diplopia n=19.
Cover test and angle of deviation
Cover test findings are shown in table 3 and angles of
deviations in table 4. The angle was significantly different
between patients on day 1 and controls (p=0.005, MW) for
near but not for distance (p=0.055 MW). Median values and
ranges for horizontal prism cover test measurements for the
patient group for near and distance are shown in table 4. The
change in horizontal angle of deviation for paired subjects
between day 1 and day 5 was not significant (p=0.069) for
near but was significant for distance (p,0.001), demonstrat-
ing a change in the eso direction. There was no difference
between those withdrawing from heroin, methadone, or a
combination of the two, and no effects from other recrea-
tional drugs taken.
Primary position distance and lateral gaze measurements
for 38 subjects where data were complete for days 1 and 5 are
given in table 4. For day 1 and for day 5 a significant
difference was shown between primary position, right and
left gaze (both p,0.01; Friedman). To determine whether
there was a change in the degree of incomitance, the change
in the angle between primary position and side gaze between
day 1 and day 5 was considered and resultant measurements
compared. Right gaze measurements showed a median
change of +2D (range 212D to +10D), not significant
(p=0.098), and left gaze measurements showed a median
change of +2D (range 28D to +10D), significant (p=0.01).
Only one subject in the patient group demonstrated a vertical
deviation in the primary position, this was the patient who
gave the history of injury; no vertical deviation was detected
on day 1 (N: 20D X for near; 2D X for distance) but on day 5 a
vertical element was present at both distances (N: 20DXT
4DRHT near; w 6D RHT distance).
Table 1 Five day detoxification programme
Time Medication Purpose
Afternoon day 1
through to midnight
day 3
Zuclopenthixol (Clopixol) 10 mg and diazepam (Valium)
10 mg orally, then zuclopenthixol 4610 mg daily with
another four doses as and if required and diazepam
4610 mg daily. Trazodone hydrochloride 150–300 mg nightly.
Sedation
Lorazepam (Ativan) up to 4 mg every 6 hours; chlorpromazine
50–100 mg every 6 hours for those with high tolerance to the
standard medication, or where patients have been abusing
benzodiazapines. Amylobarbitone/quinalbarbitone (Tiunal)
100 mg2200 mg every 6 hours if further top up needed
Additional
medication if
sedation not
adequate
Day 4 Challenge dose of oral 25 mg naltrexone (Nalorex) To flush out
remaining opiates
Day 5 Full naltrexone (Nalorex) dose (50 mg) To build block against
opiate use
Throughout Diclofenac sodium (Voltarol); hyoscine butylbromide
(Buscopan); ranitidine (Zantac); procyclidine (Kemadrin);
prochlororperazine (Stemetil), metoclopramide (Maxolon)
as required.
To relieve symptoms
or side effects of other
medication
Table 2 Number of patients using heroin substitutes and
non-prescribed drugs
Regular Irregular/occasional/in past
Methadone 28 55
DF118 5 36
Cocaine 47 3
Cannabis 46 1
LSD 26 1
Ectasy 38 0
Amphetamines 15 1
Temazepam 24 16
Diazepam 26 20
Nitrazepam 8 6
Codeine 0 3
Zopiclone 0 5
Amitryptiline 0 1
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Prism fusion range
Median values for the total fusion range for control subjects
were 41.5D for near (range 24–53) and 23D for distance
(range 8–33). For the patient group total amplitudes were
26D near (range 2–70; n=69) and 18D distance (range 4–34;
n=68) on day 1 and 24D near (range 2–57; n=45) and
14.5D (range 3–39; n=32) on day 5. The range was
significantly higher for control subjects compared with
patients on day 1 at near but not distance (p=0.013 and
p=0.494 respectively, MW). The difference at near was due
to the divergent range being lower in the patient group when
the baseline angle of deviation was taken into account.
No statistical difference existed in the total prism fusion
range between day 1 and day 5 for near or distance either
when all patients were considered (p=0.452; p=0.063
respectively, MW), or when pairing data where complete
for both examinations (p=0.189; p=0.45 respectively,
WSRT), and no significant change in absolute divergence
occurred at distance fixation (median day 126D; median day
527D; p=0.806. WSRT). The control subjects showed a
similar absolute range of divergence at distance (median 6D)
to the patient group (p=0.791, MW).
Stereoacuity
No difference was found between control subjects and
patients on day 1 (median 60 seconds of arc, p=0.752,
MW). Twenty nine of 60 patients for whom measures were
available on both days showed a reduced score (p,0.0001.
WSRT). Of the 12 patients showing an intermittent exotropia
at near on day 1, 10 achieved 60 seconds of arc or better. All
had normal binocular visual acuities.
Ocular motility
Ocular motility was within normal limits on day 1 in 54
subjects. Twenty four showed very small limitations of
abduction (,21) and five had other defects (four cases:
slight unilateral or bilateral superior oblique underactions,
one case: slight underaction left superior rectus (21)
following injury). Of those tested on day 5 (n=60), 35 were
normal, 19 showed very small limitation(s) of abduction,
four subjects had developed signs of superior oblique under-
action(s), and one inferior oblique underaction. The one case
with underaction in laevoelevation showed an increase in
this (22).
Visual acuity, convergence, and accommodation
Near visual acuity had a median of 0.00 (6/6) for both right
and left eyes for control subjects and patients on day 1 and
0.2 for patients on day 5. A significant decline was shown
between day 1 and day 5 (p,0.001 right eye; p=0.006 left
eye. WSRT). Distance visual acuity and low contrast acuity
also significantly declined in the absence of any change in
refractive error (table 5). Convergence, accommodation and
pupil size results are shown in table 5.
Medication
The only statistically significant finding was a negative
correlation between the dosage of Clopixol and the change
in the eso direction (r=20.272; p=0.033). The r2 value is
low.
DISCUSSION
The main finding of the study was the change in the distance
angle of deviation, demonstrating a change in the eso
direction. The most obvious mechanisms for this are sixth
nerve involvement and divergence insufficiency. When this
trend became apparent, lateral gaze measurements were
added to the testing regime (week 4 onwards). The median
change in side gaze measure, however, was only 2D and this
is not considered clinically indicative of sixth nerve weak-
ness. Also there was a tendency for a change in the eso
direction on side measures before detoxification.
Subtle sixth nerve involvement has been implicated in
divergence paralysis10 because of raised intracranial pressure
and in the presence of papilloedema and the condition has
been reported with ingestion11 and withdrawal of diazepam.12
Table 3 Cover test findings (numbers refer to number of patients)
Controls Day 1 Day 5 Controls Day 1 Day 5
Near Near Near Distance Distance Distance
E 2 9 19 1 9 18
E(T) 0 0 0 0 0 5
ET 0 0 1 0 0 16
X 7 59 37 5 55 14
X(T) 0 12 7 0 2 0
XT 0 0 2 0 1 0
O 1 3 3 4 16 13
Total 10 83 69 10 83 66
E = esophoria; E(T) = intermittent esotropia; ET = esotropia; X = exophoria; X(T) = intermittent exotropia; XT = exotropia; O = orthophoria.
Table 4 Horizontal prism cover test measurements
Day 1 Day 1 Day 5
Controls Median Range Patients Median Range Patients Median Range
Near n = 10 3D PBIn 8D PBIn to
8D PBOut
n = 82 8D PBIn 25D PBIn to
35D PBOut
n = 67 6D PBIn 30D PBIn to
18D PBOut
Distance n = 10 1.5D PBIn 2D PBIn to
4D PBOut
n = 83 2D PBIn 12D PBIn to
4D PBOut
n = 66 4D PBOut 14D PBIn to
16D PBOut
Primary position n = 38 2D PBIn 10D PBIn to
4D PBOut
n = 38 4D PBOut 14D PBIn to
16D PBOut
Right gaze n = 38 1.5D PBIn 4D PBIn to
8D PBOut
n = 38 8D PBOut 12D PBIn to
18D PBOut
Left gaze n = 38 2D PBIn 6D PBIn to
8D PBOut
n = 38 7D PBOut 14D PBIn to
18D PBOut
PBIn = prism base-in; PBOut = prism base-out; D = prism dioptres.
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Jacobson13 reports two series of primary and secondary cases
of divergence insufficiency, median absolute divergence
amplitudes were 2D and 4D respectively. Median values in
this current study for 6 metres were 6D on day 1 and 7D on
day 5, and no significant change was found. However,
although subjects who developed esophoria and intermittent
esotropia were included in the day 5 measurements, subjects
where a constant manifest deviation developed did not have
their angle corrected and the test performed. The level of
divergence was comparable to the control group on both day
1 and day 5 of the study at distance. The lower level of
divergence at near could be an artefact in that 15 of the
patient group and no controls diverged to as much as their
angle of deviation and so had a ‘‘negative’’ level of
divergence. This phenomenon is often seen clinically in
exophoric patients and is possibly a carryover of tenacious
proximal convergence.
Following a single dose of lorazepam 0.038 mg/kg Speeg-
Schatz et al14 found a change of +2.8D at distance fixation and
reduction of the near point of convergence by a mean of
6.3 cm without any change in subjective accommodation.
The effect was thought to be due to muscle relaxation. Two
drugs in the phenothiazine group have also been linked to
diplopia: olanzapine15 causing a concomitant esotropia and
prochlorperazine16 causing sixth nerve palsy. However, no
links were found between lorazepam or phenothiazine doses
and changes in distance angle in this study.
No differences were found in subjective accommoda-
tion between controls and patients, before and after
detoxification, and no fatigue between the first and last
measure. This is contrary to Perez et al’s findings17; they
reported reduced subjective accommodation in a group of
heroin users in a detoxification centre. However, the method
of detoxification is not given, nor stage during detoxification
at which measurements were taken. ‘‘Visual disturbances’’ or
‘‘blurred vision’’ are listed as side effects for several of the
medications used in this withdrawal programme; however,
there was no evidence of reduced accommodation on
subjective testing and only weak evidence for reduced
objective accommodation (table 5).
The number of subjects reporting blur and/or diplopia was
72.5%, higher than the 10% to 33.3% previously reported.2
This may be due to the method of detoxification. Kowal et al5
reported that diplopia was more common following rapid
detoxification (using naltrexone) and this has also been
suggested4 as causing a ‘‘physical or psychic shock’’ which
precedes the onset of acute concomitant esotropia.18 In the
current study, cover test findings showed intermittent
esotropia to be present in 10 of 14 subjects complaining of
diplopia. In 17 patients diplopia was accompanied by blur,
and only seven of these demonstrated a manifest deviation.
This is suggestive that some patients are interpreting blur as
diplopia. Pupil size was similar before and after detoxification
and so could not account for blur.
Visual acuity reduction was not due to refractive changes.
In a previous study ophthalmoscopic examination was found
to be normal following withdrawal.3 Opioid receptors have
been identified in the ganglion cell layer of the human
Table 5 Test results (mean (SD))
Test and notation Controls
All patients
completed day 1
p Values
Day 1 (paired
data) Day 5 (paired data)
p Value and
number of pairsControl v day 1
Distance RVA (logMAR) 20.01 (0.08) 0.00 (0.24) 0.563 0.01 (0.27) 0.11 (0.15) 0.001*
55
Distance LVA (logMAR) 0.02 (0.09) 0.09 (0.03) 0.833 0.02 (0.25) 0.13 (0.22) ,0.001*
55
Low contrast RVA (logMAR) 0.22 (0.1) 0.25 (0.16) 0.492 0.24 (0.16) 0.32 (0.16) ,0.001*
49
Low contrast LVA (logMAR) 0.25 (0.11) 0.25 (0.16) 0.941 0.24 (0.14) 0.3 (0.15) 0.003*
48
Pupil size RE (mm) 4.65 (0.66) 4.52 (1.22) 0.745 4.65 (1.24) 4.96 (1.14) 0.109
62
Pupil size LE (mm) 4.65 (0.67) 4.53 (1.23) 0.781 4.67 (1.25) 4.93 (1.21) 0.194
62
Convergence (cm) 7 (1.56) 7.72 (3.56) 0.531 7.49 (3.83) 10.96 (10.11) 0.012*
53
Accommodation RE (cm) 15.3 (5.58) 15.29 (5.52) 0.995 14.63 (5.14) 15.69 (5.31) 0.267
48
Accommodation LE (cm) 15.9 (7.4) 15.08 (5.18) 0.658 14.61 (4.72) 15.69 (4.98) 0.179
49
Accommodation BE (cm) 13.1 (3.2) 12.93 (4.58) 0.908 13.22 (4.85) 14.15 (6.68) 0.278
53
Accommodation BE repeated (cm) 14.5 (6.85) 12.2 (4.16) 0.139 12.24 (4.2) 13 (5.1) 0.356
42
MSE with fogging lens RE (D) +0.05 (0.23) +0.16 (0.85) 0.688 +0.06 (0.63) +0.26 (0.69) 0.129
28
MSE with fogging lens LE (D) +0.46 (0.34) +0.14 (0.63) 0.14 +0.08 (0.44) +0.22 (0.53) 0.093
26
MSE 6 metres RE (D) +0.08 (0.45) +0.1 (0.75) 0.929 20.02 (0.51) 0.068 (0.68) 0.308
36
MSE 6 metres LE (D) +0.25 (0.54) 0.11 (0.56) 0.477 +0.18 (0.49) 0.19 (0.67) 0.851
35
MSE 33 cm RE (D) 22.34 (0.18) 22.34 (0.58) 1.00 22.44 (0.36) 22.35 (0.55) 0.373
30
MSE 33 cm LE (D) 22.4 (0.29) 22.38 (0.44) 0.896 22.37 (0.43) 22.26 (0.85) 0.443
29
MSE 20 cm RE (D) 23.74 (0.42) 23.9 (0.67) 0.456 24.05 (0.63) 23.49 (0.81) 0.003*
26
MSE 20 cm LE (D) 23.86 (0.59) 23.88 (0.67) 0.924 23.87 (0.56) 23.28 (0.77) ,0.001*
26
RVA = right visual acuity; LVA = left visual acuity; RE = right eye; LE = left eye; BE = both eyes; MSE = mean spherical equivalent; D = dioptres; *significant
results.
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retina19 and withdrawal from opiates may affect the firing
rate or neurotransmission of these cells.
Opioid receptors in many parts of the brain have yet to be
identified. The onset of exotropia on intake6 of heroin and
esotropia on withdrawal4–6 and the larger exo deviations at
near in the patient group is suggestive of an active
mechanism. Although the number of participants in the
control group was small, the angle of deviation in the group
compares well with previously published literature.20 The
main difference found was that, despite the presence of eso
deviations in nine of 83 patients and only two of 10 controls
(no statistical difference shown by x2 testing for these
figures), the angle of deviation in the patient group was
significantly greater and this difference was in the exo
direction. This was statistically significant for near only,
although a trend towards this could also be said to exist in
the distance, results just failing to reach the 5% level of
significance (p=0.055). The range of angles was also much
higher in the patient group. It has been hypothesised that
there is direct involvement of mid brain neurons in the onset
of acute concomitant esotropia,21 and it is possible that cells
involved in the near or far response22–25 are affected such that
the equilibrium between convergence and divergence is
altered as tolerance to opioids increases leading to an
imbalance on withdrawal.
This study has demonstrated an eso trend at distance
fixation following detoxification. The mechanism does not
appear to be divergence insufficiency or sixth nerve involve-
ment, nor does it appear to be related to medication used
during this detoxification programme. The mechanism
remains speculative. However, where adult patients present
with distance esotropia, or a history of intermittent diplopia
which has now become constant and esotropia is present, the
history should include questions pertaining to drug abuse.
ACKNOWLEDGEMENTS
Our thanks go to staff and patients at Detox 5 for their help in
carrying out the study, and to colleagues for helpful comments on the
manuscript.
Authors’ affiliations
. . . . . . . . . . . . . . . . . . . . .
A Y Firth, Academic Unit of Ophthalmology and Orthoptics, University
of Sheffield, Sheffield, UK
S Pulling, M P Carr, A Y Beaini, Detox 5, Harrogate Clinic, Ripon Road,
Harrogate, UK
REFERENCES
1 Himmelsbach CK. The morphine abstinence syndrome, its nature and
treatment. Ann Intern Med 1941:829–39.
2 Ream NW, Robinson MG, Richter RW, et al. Opiate dependence and acute
abstinence. In:Richter RW. Medical aspects of drug abuse. Hagerstown, MD:
Harper and Row, 1975:81–123.
3 Thomas M, Cosgriff MC. Anisocoria in heroin withdrawal. Arch Neurol
1973;29:200–1.
4 Firth AY. Heroin withdrawal as a possible cause of acute concomitant
esotropia in adults. Eye 2001;15:189–92.
5 Kowal L, Mee J, Nadkarni S, et al. Acute esotropia in heroin withdrawal: a
case series. Binocul Vis Strabismus Q 2003;18:163–6.
6 Sutter FKP, Landau K. Heroin and strabismus. Swiss Med Wkly
2003;133:293–4.
7 Iqbal N. Heroin use, diplopia, largactil. Saudi Med J 2000;21:1194.
8 Beaini AY, Johnson TS, Langstaff P, et al. A compressed opiate detoxification
regime with naltrexone maintainance: patient tolerance, risk assessment and
abstinence rates. Addiction Biology 2000;5:451–62.
9 Moseley MJ, Jones HS. Visual acuity: calculating appropriate averages. Acta
Ophthalmol 1993;71:296–300.
10 Kirkham TH, Bird AC, Sanders MD. Divergence paralysis with raised
intracranial pressure. Br J Ophthalmol 1972;56:776–82.
11 Arai M, Fujii S. Divergence paralysis associated with ingestion of diazepam.
J Neurol 1990;237:45–6.
12 Hargrave MA. An odd cause of squint. Med J Aust 1972;2:967.
13 Jacobson DM. Divergence insufficiency revisited. Arch Ophthalmol
2000;118:1237–41.
14 Speeg-Schatz CI, Giersch A, Boucart M, et al. Effects of lorazepam on vision
and oculomotor balance. Binocul Vis Strabismus Q 2001;16:99–104.
15 Singh HK, Markowitz GD, Myers G. Esotropia associated with olanzapine.
J Clin Pharmacol 2000;20:488.
16 Mishra VN, Singh D. Diplopia due to phenothiazine toxicity. J Assoc
Physicians India 1989;37:799.
17 Perez JG, Mato MP, Garcia AS, et al. Intraocular motility, electrophysiological
tests and visual fields in drug addicts. Ophthal Physiol Opt 1995;15:493–8.
18 Burian HM, Miller JE. Comitant convergent strabismus with acute onset.
Am J Ophthalmol 1958;45:55–63.
19 Wamsley JK, Palacios JM, Kuhar MJ. Autoradiographic localization of opioid
receptors in the mammalian retina. Neurosci Lett 1981;27:19–24.
20 Freier BE, Pickwell LD. Physiological exophoria. Ophthalmic Physiol Optics
1983;3:267–72.
21 Hoyt CS, Good WV. Acute onset concomitant esotropia: when is it a sign of
serious neurological disease? Br J Ophthalmol 1995;79:498–501.
22 Mays LE. Neural control of vergence eye movements: convergence and
divergence neurons in midbrain. J Neurophysiol 1984;51:1091–108.
23 Judge SJ, Cumming BG. Neurons in the monkey midbrain with activity related
to vergence eye movements and accommodation. J Neurophysiol
1986;55:915–30.
24 Judge SJ. How is binocularity maintained during convergence and
divergence? Eye 1996;10:172–6.
25 Gamlin PD. Neural mechanisms for the control of vergence eye movements.
Ann NY Acad Sci 2002;956:264–72.
1190 Firth, Pulling, Carr, et al
www.bjophthalmol.com
 on 7 July 2005 bjo.bmjjournals.comDownloaded from 
